Sotalol tablet contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Contraindications== | ==Contraindications== | ||
Betapace (sotalol hydrochloride) is contraindicated in patients with bronchial asthma, sinus bradycardia | Betapace (sotalol hydrochloride) is contraindicated in patients with [[bronchial asthma]], [[sinus bradycardia]] second and third degree [[AV block]], unless a functioning [[pacemaker]] is present, congenital or acquired [[long QT syndrome]]s, [[cardiogenic shock]], uncontrolled [[congestive heart failure]], and previous evidence of [[hypersensitivity]] to Betapace.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BETAPACE (SOTALOL HYDROCHLORIDE) TABLET [BAYER HEALTHCARE PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c4caf469-f684-4f6d-98e8-b6a2fff1de98 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 18:50, 10 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Betapace (sotalol hydrochloride) is contraindicated in patients with bronchial asthma, sinus bradycardia second and third degree AV block, unless a functioning pacemaker is present, congenital or acquired long QT syndromes, cardiogenic shock, uncontrolled congestive heart failure, and previous evidence of hypersensitivity to Betapace.[1]
References
Adapted from the FDA Package Insert.